Newsroom

April 2016

• 
  Story Apr 28, 2016 Discovery

  Collaborating to unlock secrets of the microbiome

  Novartis and Broad Institute researchers explore how gut bacteria contribute to health and disease, beginning with type 1 diabetes.

• Press release Apr 27, 2016

  Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes

  Subject to approvals, Ilaris® will likely be first FDA-approved treatment for TRAPS and HIDS/MKD, and an important alternative treatment for patients with FMF  Designations support potential…
• 
  Story Apr 25, 2016 Patient Perspectives

  Patient advocacy at work: one man’s contributions to the COPD community

  Read how one caregiver established an association to provide resources for both COPD patients and caregivers.

• 
  Story Apr 25, 2016 Discovery

  Talking to: Bruno Strigini on why we're entering a transformative time in cancer care

  Accelerating Research to Get Answers Faster

• Press release Apr 21, 2016

  Novartis a enregistré un premier trimestre solide, malgré la perte d'exclusivité de Gleevec, et investi dans de nouveaux lancements pour soutenir la croissance à long terme

  Chiffre d'affaires net en hausse de 1% (tcc[1]), les produits de croissance ayant compensé l'impact du générique de Gleevec Les produits de croissance[2] ont progressé de 24% (en USD) à USD 3,9…
• Press release Apr 21, 2016

  Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth

  Net sales up 1% (cc[1]), as Growth Products offset Gleevec impact Growth Products[2] grew 24% (USD) to USD 3.9 billion, or 34% of Group net sales Cosentyx (USD 176 million) continues to grow…
• Press release Apr 21, 2016

  Novartis erzielt im ersten Quartal trotz Verlust der Exklusivrechte an Gleevec solide Ergebnisse und investiert in Neueinführungen zugunsten langfristigen Wachstums

  Der Nettoumsatz steigt um 1% (kWk[1]), da die Wachstumsprodukte die Einbussen bei Gleevec kompensieren Die Wachstumsprodukte[2] steigern den Umsatz um 24% (USD) auf USD 3,9 Milliarden bzw. 34%…
• Press release Apr 20, 2016

  Novartis drug Afinitor® significantly reduces seizures in Phase III study of patients with tuberous sclerosis complex

  Everolimus is the first adjunctive therapy shown in a prospective randomized Phase III study to achieve clinically significant seizure control in TSC patients[1]   Seizures are the most…
• 
  Story Apr 18, 2016 Discovery

  Factory foreman keeps liver’s line workers on task

  A complex protein module keeps the liver’s biochemical factory running smoothly and at capacity.

• 
  Story Apr 14, 2016 Discovery

  How scientists aim to expand immunotherapy options for cancer patients

  Read how NIBR and Dana-Farber scientists aim to expand immunotherapy options for patients

• 
  Story Apr 13, 2016 Access to Healthcare

  A life dedicated to fighting malaria

  Lake Victoria in southwestern Kenya is on the front line in the fight against malaria, and Agnes Akoth is a key figure.

• In The News Apr 08, 2016

  Beautiful Medicine: Rediscover the Power of Nature’s Exquisite Complexity